Wegovy pill (oral semaglutide)
Fastest-growing new product: over 265,000 weekly US prescriptions and more than 5 million since launch.
The numbers
What it is
Oral form of semaglutide for weight management, launched in the US after FDA approval and now rolling out to other markets. It opens obesity treatment to patients who do not want injections.
Why it matters to the stock. The pill is the main driver of obesity sales growth and the main lever on new-patient share against rival obesity drugs.
News
OCTANE real-world data: switchers to the Wegovy pill lose 4.1% in three months
Real-world OCTANE data on the Wegovy pill, presented at EASD 2026 on 30 September, showed adults who switched from injectable tirzepatide or semaglutide to the pill lost an average of 4.1% of body weight after three months on treatment.
Novo to present 44 abstracts at EASD 2026 including Wegovy pill real-world data
Novo said it will present 44 abstracts at the EASD 2026 diabetes meeting in Milan from 28 September to 2 October, covering semaglutide, CagriSema and zenagamtide.
Wegovy pill goes on sale in Germany, the first EU market
Novo launched the Wegovy pill in Germany from 1 September 2026, making Germany the first EU country to sell the tablet.
Novo Nordisk Q2 2026 profit beats forecasts and raises full-year outlook
Novo reported Q2 2026 adjusted sales of DKK 78,488 million, up 7% at constant exchange rates, and adjusted operating profit of DKK 33,389 million, up 11%.
EU approves Wegovy pill as first oral GLP-1 for weight management
The European Commission granted marketing authorisation for the Wegovy pill, once-daily oral semaglutide 25 mg, for adults with obesity or with overweight plus at least one weight-related condition.
Wegovy pill launches in the UK and UAE as US prescriptions top 265,000 a week
The Wegovy pill launched in the UAE in June and in the UK in July 2026, with early uptake described as encouraging.
Wegovy pill launches in the United Arab Emirates in June 2026
Novo Nordisk launched the Wegovy pill in the United Arab Emirates in June 2026, extending the pill beyond the US.
EU committee backs Wegovy pill, the first oral GLP-1 for weight management
The European Medicines Agency's CHMP gave a positive opinion on 22 May 2026 for the Wegovy pill, a once-daily oral semaglutide 25 mg for weight management.
Novo Nordisk Q1 adjusted sales fall 4% at CER; 2026 outlook raised to -4% to -12%
Novo Nordisk reported first-quarter reported sales of DKK 96.8 billion, inflated by the USD 4.2 billion 340B reversal.
FDA approves Lilly's oral obesity pill Foundayo, a rival to the Wegovy pill
The FDA approved Eli Lilly's once-daily orforglipron, sold as Foundayo, for obesity on 1 April 2026, after a 50-day review under a new fast-track programme.
Novo Nordisk reverses a USD 4.2 billion 340B provision, excluded from adjusted results
Novo Nordisk reversed a provision of USD 4.2 billion linked to the US 340B Drug Pricing Program, recorded in the first quarter of 2026.
Novo Nordisk launches the Wegovy pill in the US
Novo Nordisk started selling its once-daily oral semaglutide tablet for weight management to US patients on 5 January 2026.